Maintenance of Drug-Eluting Stent Patency Through Use of a Cangrelor Infusion in the Clinical Setting of Massive Pulmonary Hemorrhage and Venoarterial Extracorporeal Membrane Oxygenation

J Cardiothorac Vasc Anesth. 2017 Dec;31(6):2147-2151. doi: 10.1053/j.jvca.2017.03.028. Epub 2017 Mar 24.
No abstract available

Keywords: drug-eluting stent; pulmonary hemorrhage; stent patency; venoarterial membrane oxygenation.

Publication types

  • Case Reports

MeSH terms

  • Adenosine Monophosphate / administration & dosage
  • Adenosine Monophosphate / analogs & derivatives*
  • Combined Modality Therapy
  • Drug-Eluting Stents*
  • Electrocardiography / drug effects
  • Electrocardiography / methods
  • Extracorporeal Membrane Oxygenation / methods*
  • Hemorrhage / diagnosis
  • Hemorrhage / physiopathology
  • Hemorrhage / therapy*
  • Humans
  • Infusions, Intravenous
  • Male
  • Middle Aged
  • Platelet Aggregation Inhibitors / administration & dosage*
  • Pulmonary Edema / diagnosis
  • Pulmonary Edema / physiopathology
  • Pulmonary Edema / therapy*

Substances

  • Platelet Aggregation Inhibitors
  • Adenosine Monophosphate
  • cangrelor